发明名称 |
USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION |
摘要 |
Fatostatin, a recently described inhibitor of SREBP activation, significantly reduces the level of mutant p53 binding to the HMG-CoA reductase gene promoter. Further, fatostatin treatment had a dramatic effect on normalizing the abnormal 3D morphology of 3 strains of breast cancer cells: MDA-468 cells, MDA-231 cells, and SKBR3 cells. The results show a functional interaction with SREBPs as being critical for mutant p53-mediated upregulation of the mevalonate pathway genes. At a clinical level, inhibition of the mevalonate pathway, either alone or in combination with other therapies, offers a novel, safe and much needed therapeutic option for tumors bearing mutant p53. |
申请公布号 |
US2014364460(A1) |
申请公布日期 |
2014.12.11 |
申请号 |
US201314373147 |
申请日期 |
2013.01.18 |
申请人 |
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK |
发明人 |
Freed-Pastor William Allen;Prives Carol;Osborne Timothy |
分类号 |
A61K31/4439;C12Q1/68;A61K45/06 |
主分类号 |
A61K31/4439 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method comprising:
(a) identifying a subject having cancer, precancerous cells, or a benign tumor that has a mutated p53 gene or that expresses a mutant p53 protein or an mRNA encoding a mutant p53 protein; and (b) administering to the subject a therapeutically effective amount of an SREBP cleavage activating protein inhibitor, in an amount that reduces or eliminates the cancer, the precancerous cells, or the benign tumor. |
地址 |
New York NY US |